Zymeworks to Present at Canaccord Genuity 38th Annual Growth Conference
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today
announced that management will present at the upcoming Canaccord Genuity 38th Annual Growth Conference taking place August
8-9, 2018 in Boston, MA, USA.
The Company will provide a corporate update and present upcoming catalysts on Wednesday, August 8, 2018 at 2:00 p.m. ET.
Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available
afterwards.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of
next-generation multifunctional biotherapeutics. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated
drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product
candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase
1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in
immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been
further leveraged through multiple strategic partnerships with global biopharmaceutical companies.
Zymeworks Inc.
Investor Inquiries:
Ryan Dercho, Ph.D., 604-678-1388
ir@zymeworks.com
or
Media Inquiries:
Angela Bitting, 925-202-6211
a.bitting@comcast.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20180802005135/en/